Results 251 to 260 of about 114,702 (262)

Resistance to Non-Covalent Bruton Tyrosine Kinase Inhibitors

Oncology Times, 2022
openaire   +1 more source

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Nature Reviews Clinical Oncology, 2014
William Pao, Lecia V Sequist
exaly  

Resistance to Bruton Tyrosine Kinase Inhibitors

Hematology/Oncology Clinics of North America
openaire   +1 more source

Synthesis of Bruton’s Tyrosine Kinase Inhibitor GDC-0852

Synfacts, 2020
openaire   +1 more source

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Cancer Chemotherapy and Pharmacology, 2014
E. Marostica, J. Sukbuntherng, D. Loury, J. Jong, X. W. Trixhe, A. Vermeulen, G. Nicolao, S. O'brien, J. Byrd, R. Advani, J. Mcgreivy, I. Poggesi   +11 more
semanticscholar   +1 more source

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nature Reviews Clinical Oncology, 2017
Mizuki Nishino, Hiroto Hatabu, F Stephen Hodi   +2 more
exaly  

Targeted agents and immunotherapies: optimizing outcomes in melanoma

Nature Reviews Clinical Oncology, 2017
Jason J Luke, Keith T Flaherty, Antoni Ribas   +2 more
exaly  

The evolving landscape of tissue‐agnostic therapies in precision oncology

Ca-A Cancer Journal for Clinicians
Vivek Subbiah, Bettina Ryll, Razelle Kurzrock   +2 more
exaly  

Bruton's tyrosine kinase inhibitors for multiple sclerosis

The Lancet Neurology
openaire   +1 more source

SWITCH TO AROMATASE INHIBITOR BETTER THAN CONTINUING TAMOXIFEN

Ca-A Cancer Journal for Clinicians, 2005
exaly